Zoledronic acid injection

Pharmacological action: The pharmacological action of zoledronic acid is mainly to inhibit bone resorption. Its mechanism of action is not fully understood and may be related to multiple effects. Zoledronic acid can inhibit osteoclast activity in vitro, induce osteoclast apoptosis, and block osteoclast resorption of mineralized bone and cartilage by binding to bones. Zoledronic acid can also inhibit the enhanced osteoclast activity and bone calcium release caused by a variety of stimulating factors released by tumors. Toxicological studies: Genetic toxicity: The results of the Ames bacterial reverse mutation test, the Chinese hamster ovary cell chromosome aberration test, the Chinese hamster gene mutation test and the rat micronucleus test were all negative. Reproductive toxicity: Female rats were injected subcutaneously from 15 days before mating to the end of pregnancy.

Zoledronic acid

This product is a colorless clear liquid.

Bone pain caused by osteolytic bone metastases of malignant tumors, hypercalcemia caused by malignant tumors.

Intravenous drip. For adults, 4 mg each time, diluted with 100 ml 0.9% sodium chloride injection or 5% glucose injection, then intravenously dripped for no less than 15 minutes. Administer once every 3-4 weeks or as directed by a doctor.

The most common adverse reaction of this product is fever. Other adverse reactions mainly include: systemic reactions: fatigue, chest pain, leg edema, conjunctivitis; digestive system: nausea, vomiting, constipation, diarrhea, abdominal pain, dysphagia, anorexia; cardiovascular system: hypotension; blood and lymphatic system: anemia, hypokalemia, hypomagnesemia, hypophosphatemia, hypocalcemia, granulocytopenia, thrombocytopenia, pancytopenia; muscle and bone: bone pain, joint pain, muscle pain; kidney: increased serum creatinine value (related to the time of administration); nervous system: insomnia, anxiety, excitement, headache, lethargy; respiratory system: dyspnea, cough, pleural effusion;

1. Patients who are allergic to this product or other bisphosphonates are contraindicated; 2. Not recommended for patients with severe renal insufficiency; 3. Contraindicated for pregnant and lactating women.

This product should be used with caution when used in combination with aminoglycosides, because aminoglycosides have a synergistic effect in lowering blood calcium and may prolong the duration of hypocalcemia; when used in combination with diuretics, it may increase the risk of hypocalcemia; when used in combination with thalidomide, it will increase the risk of renal dysfunction in patients with multiple myeloma.

Store at room temperature 15-30℃ away from light. The shelf life is tentatively 12 months.

4ml:4mg (based on C5H10N2O7P2)

Chengdu Tiantai Mountain Pharmaceutical Co., Ltd.

• Founded in:

  2000-09-29

• Address:

  No. 88 Tianxing Avenue, Qionglai City, Sichuan Province

• Tax NO.:

  915101832024104543

• Registered Funds:

  75 million yuan

• Website:

  Log in to view

• Email:

  Log in to view